| Subcribe via RSS

Phase III study Cruise shows Lucentis improves vision in retinal vein occlusion patients (PharmaBiz)

July 31st, 2009 | Comments Off

Genentech, Inc, a wholly-owned member of the Roche Group, announced that the phase-III study Cruise showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in patients with macular edema due to central retinal vein occlusion.

Original post by macular degeneration – Google News

(click on the author link above to see full post)

Scary drivers make for good stories

July 31st, 2009 | Comments Off

Michele Schlough is a member of Edmond’s Challenged Pens writing group. Last winter she and her husband Charles boarded their RV and followed other Snowbirds to a Texas RV park.

Original post by The Edmond Sun, Edmond, OK

(click on the author link above to see full post)

Seniors – Beware the AARP’s Support of ObamaCare

July 31st, 2009 | Comments Off

Seniors beware! The AARP, claiming to represent you, is supporting the Obama Health Reform bill which is financed on your back.

Original post by Free Republic

(click on the author link above to see full post)

New treatment for macular degeneration

July 31st, 2009 | Comments Off

Friday, July 31, 2009 at 7:10 p.m. BACKGROUND: Age-related macular degeneration is a disease that affects older adults and slowly destroys sharp central vision.

Original post by KRCG-TV Jefferson City

(click on the author link above to see full post)

New treatment for macular degeneration (KRCG Jefferson City)

July 31st, 2009 | Comments Off

New treatment for age-related macular degeneration (AMD).

Original post by macular degeneration – Google News

(click on the author link above to see full post)

My Pharmiweb.com (PharmiWeb)

July 31st, 2009 | Comments Off

South San Francisco, Calif. 30 July 2009 Genentech, Inc ., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III study CRUISE showed Lucentis® (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in patients with macular edema due to central …

Original post by macular degeneration – Google News

(click on the author link above to see full post)

Roche’s investigational drug improves vision in patients with RVO

July 31st, 2009 | Comments Off

BASEL,A Switzerland Patients with vision loss due to a disease that causes swelling of the retina experienced improvements when treated with an investigational biotech drug from Roche, the Swiss drug maker said Thursday.

Original post by Drug Store News

(click on the author link above to see full post)

What Is Alzheimer’s Disease? What Causes Alzheimer’s Disease?

July 31st, 2009 | Comments Off

Alzheimer’s disease is a progressive neurologic disease of the brain leading to the irreversible loss of neurons and the loss of intellectual abilities, including memory and reasoning, which become severe enough to impede social or occupational functioning. Alzheimer’s disease is also known as simply Alzheimer’s, and Senile Dementia of the Alzheimer Type (SDAT) .

Original post by macular degeneration – Google News

(click on the author link above to see full post)

Learning To See With Macular Degeneration – TheDenverChannel.com

July 31st, 2009 | Comments Off

Learning To See With Macular DegenerationTheDenverChannel.comDENVER — Thirteen million Americans have AMD — age-related macular degeneration. It's the leading cause of irreversible blindness and vision impairment in …

Original post by macular degeneration – Google News

(click on the author link above to see full post)

Learning To See With Macular Degeneration

July 31st, 2009 | Comments Off

Therapy is teaching a man with macular degeneration a new way to look at the world.

Original post by TheDenverChannel.com – Health

(click on the author link above to see full post)
« Older Entries